Form 4: Ironwood Pharmaceuticals Director Receives Significant Restricted Stock Grant

Ironwood Pharmaceuticals Inc. Director Catherine Moukheibir was granted 45,000 shares of Class A Common Stock as part of her compensation, increasing her direct beneficial ownership to 117,944 shares.

Summary

• Catherine Moukheibir, a Director at Ironwood Pharmaceuticals Inc. (IRWD), acquired 45,000 shares of Class A Common Stock.
• The transaction occurred on June 10, 2025, and was reported via a Form 4 filing on June 12, 2025.
• These shares were granted as restricted stock under the company's Second Amended and Restated Non-employee Director Compensation Policy, which became effective on January 1, 2024.
• The granted shares vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year.
• Following this transaction, Ms. Moukheibir's direct beneficial ownership of Class A Common Stock increased to 117,944 shares.

Sentiment

Score: 6

Explanation: The document reports a routine, expected stock grant to a director as part of their compensation. While not a significant market-moving event, it reflects standard corporate governance and aligns director interests with shareholders, which is mildly positive.

Positives

• The grant of restricted stock to a director aligns the director's interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• The transaction is part of a pre-existing, publicly disclosed compensation policy, indicating transparency and adherence to corporate governance standards.

Future Outlook

The granted restricted stock is set to vest in full on the date immediately preceding the annual meeting of stockholders for the next calendar year, indicating future ownership and alignment with company performance.

Industry Context

The grant of restricted stock to a non-employee director is a common and standard practice within the pharmaceutical and broader corporate sectors. This compensation method is widely used to align the interests of board members with long-term shareholder value creation, encouraging directors to contribute to the company's sustained growth and performance.

Comparison to Industry Standards

• This type of equity grant for non-employee directors is consistent with compensation practices observed across the pharmaceutical industry and other publicly traded companies.
• While specific grant sizes and vesting schedules vary, the use of restricted stock as a component of director compensation is a global benchmark for corporate governance, aiming to foster long-term commitment and performance alignment.
• No specific comparable companies or projects are detailed in this filing.

Corporate Governance

Related Party Transactions

• The grant of 45,000 shares of restricted stock to Catherine Moukheibir, a Director, constitutes a related party transaction as it involves compensation from the company to a member of its board. This is a standard and disclosed form of related party dealing for director compensation.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial interests with shareholder value, as the stock's value is tied to company performance. It also reflects standard, transparent compensation practices.

Next Steps

• The vesting of the 45,000 restricted shares on the date immediately preceding the next annual meeting of stockholders.

Key Dates

Recommendation

Keywords

Ironwood Pharmaceuticals, IRWD, SEC Form 4, Insider Transaction, Stock Grant, Director Compensation, Restricted Stock, Catherine Moukheibir, Corporate Governance